Research published in Nature Biotechnology demonstrated that Brec1 can target and excise over 90% of clinical HIV-1 isolates found globally.

In October 2022, PROVIREX announced a major expansion in Hamburg’s .

The core of Hamburg’s research is , developed through directed molecular evolution by teams led by Prof. Joachim Hauber.

While modern ART allows people living with HIV (PLWH) to lead near-normal lives, it cannot eliminate the "provirus"—the viral DNA that integrates into the host's own genome. If ART is stopped, this latent reservoir reactivates, leading to viral rebound. A permanent cure requires the physical removal or permanent silencing of this integrated DNA.

Building upon the research conducted by and the University Medical Center Hamburg-Eppendorf (UKE) , this paper outlines the scientific and strategic progress made toward a functional HIV cure as of late 2022. Abstract

In 2022, Hamburg emerged as a primary hub for curative HIV research following significant investment in , a biotech startup utilizing "designer recombinase" technology. Unlike traditional antiretroviral therapy (ART) which only suppresses viral replication, the Brec1 recombinase acts as a molecular scalpel to precisely excise integrated HIV-1 DNA from the host genome. This paper details the 2022 expansion of Hamburg’s "Therapy Hub," the underlying Brec1 technology, and the transition toward Phase Ib/IIa clinical trials. 1. The Challenge: Beyond Viral Suppression

Unlike CRISPR-Cas9, which creates double-strand breaks and relies on error-prone cellular repair, Brec1 performs a concerted "cut and paste" action that is inherently error-free.